Bone Tumor Imaging — Lodwick

The radiological assessment of a bone lesion requires a systematic approach integrating multiple imaging characteristics to generate a prioritised differential diagnosis before histological confirmation. The Lodwick classification provides a validated framework for grading bone destruction patterns, which reflects the biological aggressiveness and growth rate of the lesion. Combined with patient age, lesion location, matrix pattern, cortical behaviour, and periosteal reaction, plain radiographs remain the cornerstone of initial bone tumour assessment.

• Plain radiograph is the first and most informative imaging investigation for any suspected bone lesion — more information per unit cost than any other modality for initial characterisation
• The cardinal question when approaching a bone lesion: "What is the host bone doing to the lesion?" — the bone`s response (periosteal reaction, zone of transition, cortical involvement) reflects tumour aggressiveness more than the tumour itself
• Systematic approach: patient age → lesion location (bone region; epiphysis/metaphysis/diaphysis) → matrix → zone of transition (Lodwick) → cortex → periosteal reaction → soft tissue extension

The Lodwick classification grades the pattern of medullary bone destruction, reflecting the rate of tumour growth relative to the bone`s ability to respond. Developed by Gwilym Lodwick in the 1960s, it remains clinically useful and widely applied.

• Zone of transition: the most important single radiological feature for assessing aggressiveness — narrow zone of transition (sharp margin) = slow-growing, benign behaviour; wide zone of transition (ill-defined, blending into normal bone) = aggressive, rapidly growing or malignant
• Lodwick grades I–II–III reflect progressive aggressiveness; however, histological confirmation is always required — imaging grades are probability estimates, not diagnoses

• Matrix refers to the mineralised material produced by the tumour cells — its pattern on plain film is highly specific for tumour type

• Arcs and rings calcification = chondroid matrix = chondroid tumour (enchondroma vs chondrosarcoma most common differential); the clinical question is whether it is benign or malignant — location (intramedullary vs peripheral), patient age, and imaging aggressiveness (cortical expansion, endosteal scalloping) guide this assessment

• Patient age is the single most powerful discriminator in bone tumour diagnosis — the differential diagnosis for a given lesion changes dramatically with age; most primary bone sarcomas occur in the first three decades; metastases, myeloma, and lymphoma dominate in adults over 40

• Epiphyseal lesions: giant cell tumour (skeletally mature, subarticular), chondroblastoma (skeletally immature, epiphyseal), clear cell chondrosarcoma, intraosseous ganglion, infection
• Metaphyseal lesions: osteosarcoma, non-ossifying fibroma, simple bone cyst (metaphysis/diaphysis), fibrous dysplasia, chondrosarcoma, Ewing sarcoma (can be diaphyseal or metaphyseal)
• Diaphyseal lesions: Ewing sarcoma, fibrous dysplasia, adamantinoma (tibia), lymphoma, Langerhans cell histiocytosis
• Epiphyseal lesion in a skeletally mature patient = GCT until proven otherwise; epiphyseal lesion in a skeletally immature patient = chondroblastoma until proven otherwise

• The most dangerous error in bone tumour imaging: underestimating aggressiveness because a lesion has a partially defined margin — a lesion with a mix of sharp and ill-defined margin should be treated as aggressive (IC or II) until proven otherwise; partial sclerosis does not exclude malignancy; when in doubt, refer to a specialist sarcoma centre before any intervention
• Bone scan in tumour assessment: technetium-99m MDP bone scan reflects osteoblastic activity; increased uptake = active bone remodelling; however, myeloma shows falsely low uptake (no osteoblastic reaction); Paget disease shows intense uptake; hot spots on bone scan in a patient with known carcinoma → blastic metastases (prostate, breast) vs lytic (renal, thyroid, lung, myeloma)
• Characteristic lesion-location combinations (high-yield): osteoid osteoma (proximal femur, cortex, with central nidus and surrounding sclerosis); adamantinoma (anterior cortex tibia, bubbly lytic); parosteal osteosarcoma (posterior distal femur, densely mineralised surface lesion); periosteal chondrosarcoma (cortical surface, chondroid matrix); chordoma (sacrum or clivus, midline, destructive, chondroid matrix)
• MRI role in bone tumour staging: essential for intramedullary extent (skip lesions, marrow involvement), soft tissue component, neurovascular involvement, and joint involvement; gadolinium enhancement characterises solid vs cystic components; MRI is not used for initial lesion characterisation — plain film first, then MRI for staging and surgical planning

• Lodwick IA: geographic + sclerotic margin = benign/slow; IB: geographic, no sclerosis = benign/low grade; IC: ill-defined geographic = aggressive; II: moth-eaten = malignant; III: permeative = highly malignant
• Zone of transition: most important single feature — narrow = slow/benign; wide = aggressive/malignant
• Matrix: arcs and rings = chondroid; cloud/fluffy = osteoid; ground glass = fibrous; pure lytic = no matrix (GCT, ABC, myeloma, metastasis)
• Sunburst periosteal reaction = osteosarcoma; onion skin = Ewing sarcoma; Codman triangle = aggressive (not specific to malignancy)
• Patient age is the most powerful discriminator: <20 years = primary bone tumours; >40 years = metastasis/myeloma most likely
• Epiphyseal skeletally mature = GCT; epiphyseal skeletally immature = chondroblastoma; diaphyseal = Ewing sarcoma/fibrous dysplasia
• Myeloma: no periosteal reaction; false negative bone scan — use whole-body CT or PET-CT
• Plain film first for any bone lesion; MRI for staging and surgical planning — not for initial characterisation
• Codman triangle: NOT pathognomonic of malignancy — also seen in osteomyelitis and other aggressive conditions
• Parosteal osteosarcoma: posterior distal femur; densely mineralised surface lesion; do not confuse with myositis ossificans (peripheral mineralisation)